MAP2K7 and neoplasm: Furthermore, in non-small cell lung cancer cell lines, a combination of the MEK inhibitor PD0325901 with saracatininb (AZD0530) abrogated tumour growth, enhanced mesenchymal to epithelial transition (EMT) and reduced cell migration and invasion [51].